Link: https://links.sgx.com/1.0.0/corporate-announcements/V694YR74DZ43VE51/e4a6dab2b7098935b54f8c2445f80189ec2eb4cf02bb6f53093765edd0f05df4

Summary:

• Transaction: On 2 September 2025, DISA (via Disa Digital Safety, its wholly-owned subsidiary) subscribed for an additional 560,889,768 new shares in DLL at S$0.00039515281 per share, totaling S$221,638 in cash through a rights issue.

• Resulting Ownership: DISA’s stake in DLL increased from 55.41% to 76.36%; its total investment rose to S$1,794,932.

• DLL Overview: Singapore-based, ISO13485-certified medtech firm providing AI-powered digital ophthalmology solutions for vision screening and cataract diagnostics. Recent products/initiatives include AVAT (automated visual acuity test) and MIDAS (Mobile Imaging Device for Anterior Segment).

• Use of Proceeds: Rights issue (which raised S$235,411 at a 58.9% take up rate) will fund working capital and product development/marketing for DLL’s devices and AI applications.

• Rationale: Investment strengthens DISA’s control, supports DLL’s operations, and positions for potential future upside from commercialization of medical diagnostics products.

• Financial Impact: Not expected to materially alter EPS or NTA/share for FY2025 (NTA/share remains at S$0.02); net loss per share before/after deal rises marginally from (0.02) to (0.03) S cents.

• Approvals/Disclosure: Deal is a discloseable transaction under Catalist rules but requires no shareholder approval. Management/director interests are unchanged except as regular shareholders. Announcement reviewed by SAC Capital, DISA’s sponsor.DISA Limited: Additional Investment in Digital Life Line Pte. Ltd. (DLL)

• New Investment: On 2 September 2025, DISA (through Disa Digital Safety Pte. Ltd.) increased its investment by subscribing for an additional 560,889,768 new DLL shares at S$0.00039515281 per share for S$221,638 in cash, via a rights issue.

• Ownership Change: DISA’s shareholding in DLL increased from 55.41% to 76.36%, raising its total investment to S$1,794,932.

• DLL Profile: DLL is a Singapore-based, ISO13485-certified medtech company specializing in AI-powered ophthalmic diagnostics (automated vision testing, cataract screening devices).

• Rationale: The investment supports working capital and key development/marketing initiatives for DLL's product pipeline (e.g., AVAT, MIDAS, cataract AI tool), and strengthens DISA's control over DLL and potential upside on product commercialization.

• Financial Impact: Unlikely to materially affect net tangible assets or EPS for FY2025 (NTA/share maintained at S$0.02, loss/share mildly worsens to S$0.03).

• Other Notes: No new director appointments; no change in controlling shareholders’ interests aside from regular holdings. Transaction is discloseable under Catalist rules but requires no shareholders’ vote. Announcement reviewed by DISA’s sponsor.